Key result
Treatment resistant hypertension is associated with a higher relative risk of developing major cardiovascular events and mortality compared with non-resistant hypertension.
Why the study?
Existing CVD policy models for evaluating the cost-effectiveness of hypertension treatment only include stroke, angina, MI, cardiac arrest, and all-cause mortality, prompting an evaluation of the model's completeness across regions.
What are the necessary cardiovascular disease outcomes to include in a Markov model for evaluating the cost-effectiveness of hypertension treatment?
Population
1 674 773 hypertensive adults and 499 226 adults with treatment resistant hypertension
Authors
Loading...
Treatment-resistant hypertension should be accounted for in cost-effectiveness models of hypertension therapies; extends differential CVD risk estimates for policy modeling.
Systematic Review (n=2,173,999)
What are the necessary cardiovascular disease outcomes to include in a Markov model for evaluating the cost-effectiveness of hypertension treatment?
Heart failure should be included in cardiovascular disease policy models evaluating the cost-effectiveness of hypertension treatment, particularly in Latin America, Eastern Europe, and Sub-Saharan Africa, and models should account for treatment-resistant hypertension.
Sorato et al. (2021) conducted a systematic review in Hypertension (n=2,173,999). Treatment resistant hypertension vs. Non-resistant hypertension was evaluated on Major CVD events and mortality. Treatment resistant hypertension is associated with a higher relative risk of developing major cardiovascular events and mortality compared with non-resistant hypertension.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: